Alexion lures Biogen exec to become its CFO

Following a boardroom shake up last month by its new chief executive Ludwig Hantson, US biotech firm Alexion Pharmaceuticals (Nasdaq: ALXN) yesterday announced that Paul Clancy, a seasoned financial executive with 30 years of experience, will join the company on July 10, 2017 and will assume the role of chief financial officer (CFO) effective July 31, 2017.

For the past 16 years, Mr. Clancy has been employed by Biogen (Nasdaq: BIIB), where he has served as CFO for the last 10 years. Prior to Biogen, Mr Clancy spent 13 years with PepsiCo in various executive positions. Mr Clancy will succeed Dave Anderson, who will continue to serve as CFO until July 31. To ensure a smooth transition, Mr Anderson will then become a senior advisor to the chief executive and will remain with Alexion until the end of August.

“I couldn’t be more pleased to welcome Paul to Alexion,” said Ludwig Hantson, CEO of Alexion. “Paul is a world-class CFO who has distinguished himself in the biopharmaceutical industry. He brings deep experience and a proven track record of managing a global organization, executing successful financial and capital allocation strategies to deliver long-term shareholder value, and cultivating strong relationships with the investment community. He is an outstanding addition to our team and we look forward to his leadership, insights and partnership as we position Alexion for its next stage of growth.”